B.C. massage therapist banned from touching parts of female patients' bodies
Update: The limits on Stephen Glover's practice were lifted in December 2024.
A B.C. massage therapist has been prohibited from massaging certain parts of female patients' bodies while a misconduct investigation is underway, according to the professional regulator.
Stephen Glover, of Powell River, is being investigated after a patient submitted a complaint to the College of Massage Therapists of B.C.
The woman he treated alleged that he 'provided a draping option to the patient that involved the complete exposure of a sensitive area of the patient's body' and that he 'massaged a sensitive area of the patient's body,' according to a notification posted online Tuesday.
While the allegations have not been proven, the college issued an interim order restricting Glover's practise 'to protect the public.'
The area that Glover is not allowed to treat is described in detail and encompasses, basically, the entire front torso below the collarbone and above the hips.
'This limit includes treating over the draping,' the interim order says.
Glover is also required to post a notice of these limits, approved by the college, anywhere he is working.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
CIBC Innovation Banking Provides Growth Capital Financing to MedMe Health
Article content TORONTO — CIBC Innovation Banking announced today that it has provided a growth-focused credit facility to MedMe Health ('MedMe'). The company will use the financing to expand its product suite and scale its operations in North America. Article content Founded in 2019, MedMe has rapidly established itself as a leading platform for pharmacy care delivery in Canada, supporting over 4,500 pharmacies across North America. MedMe enables pharmacies to operate as true clinical hubs, delivering vaccinations, chronic disease management, and preventative care at scale. Article content 'With growing traction in the US and the launch of AI-powered tools such as Clinical Assistant and Patient Concierge, MedMe is setting a new standard for how community providers engage, document, and care for patients,' said Purya Sarmadi, CEO and Co-Founder of MedMe. 'We are excited to work with CIBC Innovation Banking to fuel our next stage of growth. This financing will accelerate our US expansion, extend our medical billing capabilities for pharmacist-led care, advance our AI roadmap, and scale our presence across specialty pharmacy and adjacent healthcare providers.' Article content Niramay, Executive Director at CIBC Innovation Banking, added 'MedMe is helping to transform pharmacy care delivery with its innovative, customizable software platform. We are proud to support its next phase of growth as it expand into new markets and continues to drive digital transformation in the healthcare sector.' Article content MedMe is backed by leading investors including Microsoft's M12, Graphite Ventures, MaRS IAF, and YCombinator. Article content About CIBC Innovation Banking Article content CIBC Innovation Banking has 25 years of specialized experience in growth-stage tech and life science companies across North America – a longer track record than most banks. CIBC Innovation Banking now has over $11 billion in funds managed including life sciences, health care, cleantech companies, investors, and entrepreneurs, and has assisted over 700 venture and private equity-backed businesses over the past six and a half years. The bank operates out of 14 global locations in San Francisco, Menlo Park, New York, Toronto, London, Austin, Boston, Chicago, Seattle, Vancouver, Montreal, Atlanta, Reston, and Durham. Connect with us today to start the conversation. About MedMe Health MedMe Health is a scaling-stage digital health company transforming how pharmacies and community-based providers deliver care. Founded to address the growing gap between traditional pharmacy systems and the clinical demands of modern practice, MedMe replaces fragmented, outdated tools with a configurable, all-in-one platform built specifically for pharmacist-led care. Article content Trusted by over 4,500 pharmacy locations and leading national chains across North America, MedMe's platform has powered more than 25 million patient services to date. The company is expanding rapidly across the US and adjacent verticals such as specialty pharmacy. MedMe's modular infrastructure streamlines scheduling, intake, documentation, and communication for pharmacy clinical services such as vaccinations, minor ailments, POCT, and chronic disease management. Article content MedMe is also leading the integration of AI in pharmacy care. Its Clinical Assistant transcribes and auto-fills clinical notes in real time, while Patient Concierge, a voice agent, autonomously answers and makes calls to handle refills, bookings, and follow-ups. These tools reduce administrative burden, improve access, and enable pharmacists to operate at the top of their license. Article content Article content Article content Article content Article content Article content
National Post
an hour ago
- National Post
Covalon Technologies Ltd. Achieves DTC Eligibility in the United States
Article content Improving Access for U.S. Investors and Supporting Share Price Appreciation for Canadian MedTech Innovator Article content MISSISSAUGA, Ontario — Covalon Technologies Ltd. (the 'Company' or 'Covalon') (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that its common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company ('DTC'). Article content DTC eligibility simplifies the trading process for Covalon shares on the U.S. OTCQX Market under the symbol CVALF by eliminating manual delays and higher transaction costs often associated with cross-border securities. Article content Most United States-based brokerage firms do not allow their customers to trade shares unless they are DTC eligible. This accomplishment will enable Covalon to generate increased U.S. interest, which will enhance liquidity and improve Covalon's positioning in the United States, where companies with Covalon's financial performance trade at much higher market values. Article content ' This is a major milestone for Covalon as we expand our visibility and access to a broader investor base, ' said Brent Ashton, CEO of Covalon. ' Receiving DTC eligibility significantly streamlines the investment process for U.S. shareholders and demonstrates the commitment to growing our presence in U.S. capital markets, where we have received very positive feedback from investors.' In addition, in the Company's May 15, 2025 press release, Covalon announced the promotion of Kim Crooks appointment to Covalon's Board of Directors, and the awarding of 150,000 common share stock options, both of which were subject to the approval of the TSX Venture Exchange. Article content The Options were granted pursuant to the Company's Omnibus Long-Term Incentive Plan on May 30, 2025, and are subject to the terms of the applicable grant agreement, the requirements of the TSX Venture Exchange, and shareholder approval at the Company's next Annual General Meeting, scheduled in early 2026. Article content The Options were granted at an exercise price of $2.50 per share, effective May 30, 2025. The options vest 34% on the first anniversary of the grant date, 33% on the second anniversary, and the remaining 33% on the third anniversary. The Options shall expire five (5) years from the initial grant date. Article content About Covalon Article content Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Article content . Article content Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Article content This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan', 'estimate', 'expect', 'intend', or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at Article content Article content , any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. Article content Article content Article content
National Post
an hour ago
- National Post
Why food recalls have increased so drastically in the last decade in Canada
Last year, it was plant-based refrigerated beverages. This summer, it's Dubai chocolate, which went from viral fame to plain old virulent, with the Canadian Food Inspection Agency (CFIA) recalling several brands due to Salmonella contamination. Article content It's not your imagination — there are more food recalls today than a decade ago, though the number has stayed relatively stable over the past five years. Experts say the reason why comes down to a couple of key factors: improved detection methods and regulations that modernized Canada's food safety system. Article content When Sylvain Charlebois, senior director of Dalhousie University's Agri-Food Analytics Lab (AAL), posted a graph of the number of food recalls in Canada since 2011 on social media last week, some of his followers expressed surprise and concern. The graph showed a dramatic jump from 45 recalls in 2018 to 259 in 2019, remaining well above 100 ever since (with two years surpassing 250). Article content Number of food recalls in Canada, since 2011 (Class, 1, 2 and 3). — The Food Professor (@FoodProfessor) August 15, 2025 Article content Our food safety culture is 'very strong,' says Charlebois, pointing to Canadians' reluctance to eat perfectly edible products past their best-before dates. Food recalls don't necessarily mean that our food system is unsafe — he sees them as a sign that it's maturing in a positive way. Article content 'People tend to become quite nervous as soon as they see a metric that would suggest, perhaps, that things aren't going in the right direction, but they are in terms of food recalls.' Article content Some recalls, such as the recent outbreak of Salmonella infections linked to various brands of pistachios and pistachio-containing products, such as Dubai chocolate, cause illnesses and hospitalizations, but many others are preventative. Though recalls due to microbiological hazards were the most prevalent from April 1, 2020, to March 31, 2025, they can also result from allergens, extraneous material, chemicals and other reasons. Article content 'Even in a modern, effective food safety system such as Canada's, risks cannot be completely eliminated. When unsafe food enters the marketplace, the CFIA works with the company to ensure that the public is informed and that the recall was effective at removing products from the market,' the CFIA said in an email to National Post. Article content 'Consumers can help protect themselves and their families by following safe food handling practices at home and staying informed about food recalls by signing up for food recall notifications.' Article content Article content Keith Warriner, a professor at the University of Guelph's Department of Food Science, highlights that the means of detecting outbreaks are much better than they were 10 years ago, 'if not five years ago.' Sophisticated surveillance systems and advanced techniques, such as whole genome sequencing, have made it easier to identify risks. Article content Companies are also doing more testing, which increases the likelihood of finding something warranting a recall, says Warriner. 'Even though no outbreaks are involved, they'll do it as a precaution. And you'll see microgreen producers, for example, they've had quite a few recalls of Listeria. Even though there's been no real outbreaks of Listeria with microgreens, they preempt it because they do a lot of testing.'
